Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05761951 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer

A Phase 2 study of Endometrial Cancer, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
8
Enrollment target
1
Study location

NCT05761951 is a Phase 2 study of Endometrial Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05761951, a Phase 2 study of Endometrial Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer.

Conditions Studied

Endometrial Cancer

Interventions

  • DRUG Pembrolizumab
  • DRUG DKN-01

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2023-08-29
Est. Completion 2029-01-31
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05761951

The ClinicalTrials.gov registry entry for NCT05761951 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (98% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.

NCT05761951 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT05761951 about?

NCT05761951 is a clinical study titled "Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer". To learn if the combination of DKN-01 and pembrolizumab can help to control advanced or recurrent endometrial cancer.

What is the current status of trial NCT05761951?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2023-08-29. Estimated completion is 2029-01-31.

What conditions does trial NCT05761951 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT05761951?

The interventions under investigation include: Pembrolizumab (DRUG), DKN-01 (DRUG).

Who is sponsoring clinical trial NCT05761951?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05761951 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Cancer

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.